Article Link: FDA Approves Elyxyb (celecoxib) Oral Solution For Acute Treatment Of Migraine With Or Without Aura In Adults HYDERABAD, Ind...
This Week’s Featured Biotech Stock up Over 80% on Day Two of Our Coverage
Update- Genprex (NASDAQ: GNPX), Breaking news this morning: Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combin...
FDA Approves Fensolvi (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty
Article Link: FDA Approves Fensolvi (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty ...
FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma
Article Link: FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma HORSH...
2020 is shaping up to be a very profitable year for our members, We want to make it the best we have ever had!
We are working on a new report that could move fast and furious early next week. Details below. Good day everyone, Welcome to all our new members and ...
FDA Approves Zejula (niraparib) as the Only Once-Daily PARP Inhibitor in First-Line Monotherapy Maintenance Treatment for Women with Platinum-Responsive Advanced Ovarian Cancer Regardless of Biomarker Status
Article Link: FDA Approves Zejula (niraparib) as the Only Once-Daily PARP Inhibitor in First-Line Monotherapy Maintenance Treatment for Women with Pla...
FDA Approves Ortho Dermatologics' Labeling for Jublia (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old
Article Link: FDA Approves Ortho Dermatologics’ Labeling for Jublia (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old...
FDA Approves Merck’s Keytruda (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Article Link: FDA Approves Merck’s Keytruda (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult...
BioSig Technologies (NASDAQ: BSGM) Featured on Fox Business Following our Initial Report
Biosig (NASDAQ: BSGM) subsidiary ViralClear Pharmaceuticals CEO Interviewed on "The Claman Countdown" FOX BUSINESS
FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
Article Link: FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes ...